Neumeister B, Woerndle S, Bartmann P
Abteilung Medizinische Mikrobiologie und Hygiene, Universität Ulm, Deutschland.
Biol Neonate. 1996;70(2):128-34. doi: 10.1159/000244357.
Several lines of evidence suggest that surfactant and surfactant proteins may have direct effects on inhaled bacteria and are able to interact with lung defence mechanisms in many ways. We examined the effect of three different surfactant preparations (Alveofact, Survanta and Exosurf) approved for treatment of the infant respiratory distress syndrome on different strains of Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus agalactiae which are important neonatal pathogens and on Legionella pneumophila serogroup I as a frequent cause of pneumonia in adults. Addition of Survanta to saline seemed to delay the reduction of viable bacteria in sterile saline and induced a considerably accelerated growth of all examined E. coli strains. As opposed to this, addition of surfactant did not influence the kinetics of bacterial growth in brain-heart infusion or buffered yeast extract both with the exception of Exosurf which exerted an inhibitory effect on the multiplication of group B streptococci. Though the exact mechanisms underlying these effects remain to be determined, the influence of surfactant therapy on the growth of bacteria within the respiratory tract should be taken into account.
多项证据表明，表面活性剂和表面活性蛋白可能对吸入的细菌有直接作用，并能够在许多方面与肺部防御机制相互作用。我们研究了三种被批准用于治疗婴儿呼吸窘迫综合征的不同表面活性剂制剂（Alveofact、Survanta和Exosurf）对不同菌株的影响，这些菌株包括作为重要新生儿病原体的大肠杆菌、金黄色葡萄球菌、表皮葡萄球菌和无乳链球菌，以及作为成人肺炎常见病因的嗜肺军团菌血清群I。向盐水中添加Survanta似乎会延迟无菌盐水中活菌数量的减少，并导致所有检测的大肠杆菌菌株生长显著加速。与此相反，除了Exosurf对B组链球菌的增殖有抑制作用外，添加表面活性剂对脑心浸液或缓冲酵母提取物中的细菌生长动力学没有影响。尽管这些作用的确切机制仍有待确定，但应考虑表面活性剂治疗对呼吸道内细菌生长的影响。
